Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After Chemotherapy
Conditions: Transitional Cell Tumor; Hepatoblastoma; Liver Cancer; Pediatric Solid Tumor; Pediatric Cancer Intervention: Drug: PD-1 inhibitor Sponsor: RenJi Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Chemotherapy | Hepatoblastoma | Hospitals | Pediatrics | Research